文献速递甲状腺疾病

仑伐替尼联合帕博利珠单抗治疗转移性BRAF野生型未分化甲状腺癌的真实世界经验

Real-World Experience with Lenvatinib plus Pembrolizumab in Metastatic BRAF Wild-Type Anaplastic Thyroid Carcinoma.
PubMed 文献 · Thyroid · 2026-01-07

该单中心回顾性研究纳入36例2016年1月至2024年7月接受一线仑伐替尼联合帕博利珠单抗治疗的转移性BRAF野生型未分化甲状腺癌患者,中位随访39.5个月,中位OS为7.7个月,中位PFS为6.2个月,确认ORR为36%,中位缓解持续时间16.0个月,安全性与既往研究相似。

要点

  • 仑伐替尼联合帕博利珠单抗在BRAF野生型未分化甲状腺癌中显示临床疗效。
  • 确认ORR为36%,中位OS 7.7个月,中位PFS 6.2个月。
  • 14%患者因免疫相关毒性停用帕博利珠单抗。

核心结论

  • 真实世界中仑伐替尼联合帕博利珠单抗治疗转移性BRAF野生型未分化甲状腺癌显示临床疗效和安全性,与既往报道一致。

研究设计与样本

  • 回顾性单中心研究,纳入36例2016年1月至2024年7月在临床试验外接受一线仑伐替尼联合帕博利珠单抗治疗的BRAF野生型未分化甲状腺癌患者。

主要发现

  • 中位随访39.5个月(CI 8.1-54.3),中位OS为7.7个月(CI 4.6-22.9),中位PFS为6.2个月(CI 3.1-7.9)。
  • 33/36例可评估患者中确认ORR为36%,中位缓解持续时间16.0个月(CI 3.2-28.8)。
  • 最佳总缓解:确认完全缓解3例(9%),确认部分缓解9例(28%),疾病稳定11例(33%),疾病进展10例(30%)。
  • 5例(14%)因免疫相关毒性停用帕博利珠单抗,包括肺炎2例和结肠炎3例。
  • 2例因担心食管或气管瘘停用仑伐替尼,但均无需进一步干预。

关键数值与推荐

  • 仑伐替尼中位初始剂量16 mg(IQR 10-20 mg)。
  • 帕博利珠单抗给药方案:200 mg每3周(64%)或400 mg每6周(36%)。
  • PD-L1联合阳性评分≥1见于96%(27/28)可评估标本,中位肿瘤突变负荷2 mut/Mb(IQR 1-4),高微卫星不稳定性见于7%(2/30)。

临床怎么用

  • 对于转移性BRAF野生型未分化甲状腺癌,可考虑仑伐替尼联合帕博利珠单抗作为一线治疗选择。
  • 治疗中需监测免疫相关毒性,尤其是肺炎和结肠炎。
  • 需关注食管或气管瘘风险,必要时停用仑伐替尼。

局限性

  • 回顾性单中心研究,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: BRAF wild-type anaplastic thyroid carcinomas (BRAFWT-ATCs) have a poor prognosis, in part, due to limited effective therapies. The preliminary results from the phase II ATLEP trial suggest the promising clinical activity of lenvatinib plus pembrolizumab (L/P). We aimed to confirm the real-world efficacy of L/P in BRAFWT-ATC. METHODS: A retrospective single-center study of patients with BRAFWT-ATC treated with first-line L/P between January 2016 and July 2024 outside of a clinical trial. The primary endpoints were confirmed overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). RESULTS: In 36 eligible patients, the median age at treatment start was 64 years (range, 41-84 years). All patients had distant metastases, and 46% had radiological suspicion of locoregional invasion, including that of the trachea, esophagus, and/or internal jugular vein. The most common driver mutations were RAS (39%) and NF1 (19%); 61% had co-occurring TP53 and 50% TERT promoter mutations. In the evaluated specimens, programmed cell death ligand 1 (PD-L1) combined positive score was ≥1 in 96% (27/28), median tumor mutational burden was 2 mut/Mb (interquartile range [IQR], 1-4), and high microsatellite instability (MSI-H) was present in 7% (2/30). Previous therapies for ATC included surgery (69%), definitive- (31%) or palliative-intent (31%) neck external beam radiation, and cytotoxic chemotherapy (9%). The median initial lenvatinib dose was 16 mg (IQR, 10-20 mg). Pembrolizumab dosing was 200 mg Q3 weeks (64%) or 400 mg Q6 weeks (36%). The median time between lenvatinib and pembrolizumab initiation was 0.5 days (IQR, -7.8 to 10.5). With a median follow-up of 39.5 months [confidence interval {CI}, 8.1-54.3], the median OS was 7.7 months [CI, 4.6-22.9], and the median PFS was 6.2 months [CI, 3.1-7.9]. In 33/36 patients evaluable for responses, the confirmed ORR was 36%, and the median duration of the response was 16.0 months [CI, 3.2-28.8]. The best overall response was confirmed complete response in 3 (9%), confirmed partial response in 9 (28%), stable disease in 11 (33%), and progressive disease in 10 (30%) patients. The safety profile was similar to previous studies. Five (14%) patients stopped pembrolizumab due to immune-related toxicity, including pneumonitis (n = 2) and colitis (n = 3). Two patients discontinued lenvatinib due to concern for esophageal or tracheal fistula; however, no further intervention was required in either case. CONCLUSIONS: Our real-world experience with L/P in metastatic BRAFWT-ATC demonstrates the clinical efficacy and safety of this combination, consistent with prior reports. A prospective clinical trial in the United States is ongoing (NCT#04171622).

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Hamidi S, Vodopivec DM, Busaidy NL, et al. Real-World Experience with Lenvatinib plus Pembrolizumab in Metastatic BRAF Wild-Type Anaplastic Thyroid Carcinoma. Thyroid. 2026. PMID: 41791883. doi:10.1177/10507256251409138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。